GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » EPS without NRI

Flexion Therapeutics (Flexion Therapeutics) EPS without NRI : $-1.98 (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics EPS without NRI?

Flexion Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2021 was $-0.60. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.98.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Flexion Therapeutics's EPS without NRI or its related term are showing as below:

FLXN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.1   Med: -18.8   Max: 15.3
Current: 15.3

FLXN's 3-Year EPS without NRI Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 11.65 vs FLXN: 15.30

Flexion Therapeutics's EPS (Diluted) for the three months ended in Sep. 2021 was $-0.60. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.98.

Flexion Therapeutics's EPS (Basic) for the three months ended in Sep. 2021 was $-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.98.


Flexion Therapeutics EPS without NRI Historical Data

The historical data trend for Flexion Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics EPS without NRI Chart

Flexion Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.84 -4.16 -4.49 -3.93 -2.53

Flexion Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.37 -0.57 -0.44 -0.60

Competitive Comparison of Flexion Therapeutics's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Flexion Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Flexion Therapeutics's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Flexion Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Flexion Therapeutics's PE Ratio without NRI falls into.



Flexion Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Flexion Therapeutics  (NAS:FLXN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Flexion Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Flexion Therapeutics (Flexion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
Mark S. Levine officer: General Counsel 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth officer: Chief Regulatory Officer AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth officer: Chief Strategy Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman officer: Chief Commercial Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley officer: Chief Medical Officer C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman director, officer: President and CEO C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield director
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy director C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Flexion Therapeutics (Flexion Therapeutics) Headlines